Search research articles
Contact Us
Filters
Showing results (141-150 of 301) with videos related to
Page
of 31
Sort By:
The Lancet. Haematology
|
December 22, 2015
Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study
Paul G Richardson, Sundar Jagannath, Philippe Moreau, et al.
Haematologica
|
June 27, 2020
Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
Fredrik H Schjesvold, Paul G Richardson, Thierry Facon, et al.
The New England Journal of Medicine
|
November 23, 2007
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Meletios Dimopoulos, Andrew Spencer, Michael Attal, et al.
Leukemia & Lymphoma
|
May 3, 2008
Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia
Xavier Leleu, Anne-Sophie Moreau, Edie Weller, et al.
Blood
|
April 7, 2021
Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results
Murielle Roussel, Valerie Lauwers-Cances, Soraya Wuilleme, et al.
The Lancet. Oncology
|
September 24, 2013
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study
Meletios Dimopoulos, David S Siegel, Sagar Lonial, et al.
Blood
|
June 15, 2011
Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials
Peter M Fayers, Antonio Palumbo, Cyrille Hulin, et al.
British Journal of Haematology
|
May 26, 2021
Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics
Simon J Harrison, Aurore Perrot, Adrian Alegre, et al.
Haematologica
|
August 23, 2023
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma
Paul G Richardson, Brian G Durie, Laura Rosiñol, et al.
Blood Advances
|
July 8, 2026
TNFRSF17 genomic profiling guides retreatment with alternative BCMA-directed immunotherapies in multiple myeloma
Benjamin Podvin, Holly Lee, Remi Tilmont, et al.
Page
of 31
Search research articles
Search
Showing results (141-150 of 301) with videos related to
Sort By:
Page
of 31
The Lancet. Haematology
|
December 22, 2015
Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study
Paul G Richardson, Sundar Jagannath, Philippe Moreau, et al.
Haematologica
|
June 27, 2020
Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
Fredrik H Schjesvold, Paul G Richardson, Thierry Facon, et al.
The New England Journal of Medicine
|
November 23, 2007
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Meletios Dimopoulos, Andrew Spencer, Michael Attal, et al.
Leukemia & Lymphoma
|
May 3, 2008
Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia
Xavier Leleu, Anne-Sophie Moreau, Edie Weller, et al.
Blood
|
April 7, 2021
Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results
Murielle Roussel, Valerie Lauwers-Cances, Soraya Wuilleme, et al.
The Lancet. Oncology
|
September 24, 2013
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study
Meletios Dimopoulos, David S Siegel, Sagar Lonial, et al.
Blood
|
June 15, 2011
Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials
Peter M Fayers, Antonio Palumbo, Cyrille Hulin, et al.
British Journal of Haematology
|
May 26, 2021
Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics
Simon J Harrison, Aurore Perrot, Adrian Alegre, et al.
Haematologica
|
August 23, 2023
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma
Paul G Richardson, Brian G Durie, Laura Rosiñol, et al.
Blood Advances
|
July 8, 2026
TNFRSF17 genomic profiling guides retreatment with alternative BCMA-directed immunotherapies in multiple myeloma
Benjamin Podvin, Holly Lee, Remi Tilmont, et al.
Page
of 31